Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today

NEW YORK (TheStreet) -- AcelRx Pharmaceuticals  (ACRX) plummeted Monday after the FDA rejected the company's painkiller dispensing device Zalviso.

AcelRx announced the news late Friday that the FDA did not grant approval to the device. The FDA has some concerns about Zalviso and has asked for more data to "support the shelf life of the product," according to the agency's Complete Response Letter.

For more on this story, read TheStreet's Adam Feuerstein's article here.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 34.81% to $7.06 at 10:07 a.m.

ACRX Chart ACRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking